San Diego-headquartered pharmaceutical company Arcadia has named Albert Kildani as its new senior vice president of IR and corporate communications.
Kildani joins the business with more than 10 years’ experience in the pharmaceutical and biotechnology sectors, having previously worked for companies such as Halozyme Therapeutics, Vital Therapies, Hologic and Gen-probe.
Arcadia is focused on neuroscience. It developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome.
The firm’s executive vice president and CFO Mark Schneyer says both Kildani’s experience working in similar roles within companies and his years as a Wall Street analyst will play a crucial role in the firm’s future strategy.
‘His strong network of relationships and his proven expertise in building shareholder value will be instrumental as we continue to advance our global business strategy to deliver important therapeutics for central nervous system disorders,’ he says.
Kildani notes his appointment comes at a time of ‘transformational growth’.
‘I am excited to join Acadia during this time of transformational growth as we deliver two important and commercially available therapeutics in areas of high unmet medical need to the patient community,’ he says.
